3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one | 83387-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one
• CAS: 83387-25-1
• 化学式: C₂₁H₂₆NO₄
• 分子量: 356.442
• InChiKey: JVLBPIPGETUEET-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts
  申请人：Wang Peter X.

  公开号：US20100035910A1

  公开（公告）日：2010-02-11

  An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.

  将三级吗啡类生物碱进行N-烷基化，形成相应的季铵盐型吗啡类生物碱衍生物的改进过程。
• [EN] N-DEMETHYLATION OF N-METHYL MORPHINANS<br/>[FR] N-DÉMÉTHYLATION DE N-MÉTHYL MORPHINANES
  申请人：MALLINCKRODT INC

  公开号：WO2009078990A1

  公开（公告）日：2009-06-25

  The present invention provides a synthetic process for the N-demethylation of N-methyl morphina'ns. In particular, the invention provides improved synthetic methods for the preparation of N-demethylated morphinan compounds that may be employed as starting materials, for example, commonly available N-methyl opiates such as oripavine and thebaine, and C (3) -protected hydroxy derivatives of oripavine.

  本发明提供了一种合成N-去甲基化N-甲基吗啡的过程。特别是，本发明提供了改进的合成方法，用于制备N-去甲基化的吗啡类化合物，这些化合物可以作为起始材料，例如常见的N-甲基鸦片碱，如奥利帕啡和吗啡，以及奥利帕啡的C（3）-保护羟基衍生物。
• Multi-arm polymer prodrugs
  申请人：Zhao Xuan

  公开号：US20080194612A1

  公开（公告）日：2008-08-14

  Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

  本文提供了一种水溶性的前药。该发明的前药包括一个水溶性聚合物，具有三个或更多的臂，其中至少三个臂与活性剂（例如小分子）共价连接。本发明的结合物提供了聚合物大小和结构的最佳平衡，以实现改善药物负载，因为本发明的结合物具有三个或更多的活性剂可释放地连接到多臂水溶性聚合物上。本发明的前药具有治疗效果，并在体内表现出比未修改的母体药物更好的性能。
• Multi-Arm Polymer Prodrugs
  申请人：Zhao Xuan

  公开号：US20090074704A1

  公开（公告）日：2009-03-19

  Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

  本文提供了水溶性前药、包含这种前药的组合物以及相关的制备和使用方法。本发明的前药包括具有三个或更多臂的水溶性聚合物，其中至少三个臂通常共价地连接到一个活性剂，例如小分子。本发明的共轭物提供了聚合物尺寸和结构的最佳平衡，以实现改进的药物装载，因为本发明的共轭物具有三个或更多的活性剂可释放地连接到多臂水溶性聚合物上。本发明的前药具有治疗效果，并且与未经修改的母药相比，在体内表现出改进的性质。
• MULTI-ARM POLYMER PRODRUGS
  申请人：Zhao Xuan

  公开号：US20100190933A1

  公开（公告）日：2010-07-29

  Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

  本文提供的是水溶性前药。该发明的前药包括具有三个或更多臂的水溶性聚合物，其中至少三个臂与活性剂（例如小分子）共价连接。本发明的结合物提供了最佳的聚合物大小和结构平衡，以达到改进药物负载的目的，因为本发明的结合物具有三个或更多活性剂可释放地附着于多臂水溶性聚合物上。本发明的前药在治疗上是有效的，并且与未经修改的原始药物相比，在体内表现出改进的性质。